Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

Drew J. Winston, Andrew M Yeager, Pranatharthi H. Chandrasekar, David R. Snydman, Finn Bo Petersen, Mary C. Territo, Kathy Bartoni, Ken Miller, David Schenkein, Patrick Stiff, Reid Mattison, Mary Laughlin, Witold Rybka, Margarida De Magalhaes-Silverman, John R. Wingard, Toni Mazzuli, Clare Brennan, Sharon McDermott, Mauricio Vargas, Ira C. Lee

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)749-758
Number of pages10
JournalClinical Infectious Diseases
Volume36
Issue number6
DOIs
StatePublished - Mar 15 2003
Externally publishedYes

Fingerprint

valacyclovir
Ganciclovir
Homologous Transplantation
Cytomegalovirus
Bone Marrow Transplantation
Transplantation
Confidence Intervals
Acyclovir
Cytomegalovirus Infections
Bone Marrow

ASJC Scopus subject areas

  • Immunology

Cite this

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. / Winston, Drew J.; Yeager, Andrew M; Chandrasekar, Pranatharthi H.; Snydman, David R.; Bo Petersen, Finn; Territo, Mary C.; Bartoni, Kathy; Miller, Ken; Schenkein, David; Stiff, Patrick; Mattison, Reid; Laughlin, Mary; Rybka, Witold; De Magalhaes-Silverman, Margarida; Wingard, John R.; Mazzuli, Toni; Brennan, Clare; McDermott, Sharon; Vargas, Mauricio; Lee, Ira C.

In: Clinical Infectious Diseases, Vol. 36, No. 6, 15.03.2003, p. 749-758.

Research output: Contribution to journalArticle

Winston, DJ, Yeager, AM, Chandrasekar, PH, Snydman, DR, Bo Petersen, F, Territo, MC, Bartoni, K, Miller, K, Schenkein, D, Stiff, P, Mattison, R, Laughlin, M, Rybka, W, De Magalhaes-Silverman, M, Wingard, JR, Mazzuli, T, Brennan, C, McDermott, S, Vargas, M & Lee, IC 2003, 'Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation', Clinical Infectious Diseases, vol. 36, no. 6, pp. 749-758. https://doi.org/10.1086/367836
Winston, Drew J. ; Yeager, Andrew M ; Chandrasekar, Pranatharthi H. ; Snydman, David R. ; Bo Petersen, Finn ; Territo, Mary C. ; Bartoni, Kathy ; Miller, Ken ; Schenkein, David ; Stiff, Patrick ; Mattison, Reid ; Laughlin, Mary ; Rybka, Witold ; De Magalhaes-Silverman, Margarida ; Wingard, John R. ; Mazzuli, Toni ; Brennan, Clare ; McDermott, Sharon ; Vargas, Mauricio ; Lee, Ira C. / Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. In: Clinical Infectious Diseases. 2003 ; Vol. 36, No. 6. pp. 749-758.
@article{f7882c8472e8402196cb439dbed38af2,
title = "Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation",
abstract = "In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12{\%} of the patients who received valacyclovir and in 19{\%} of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95{\%} confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95{\%} CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.",
author = "Winston, {Drew J.} and Yeager, {Andrew M} and Chandrasekar, {Pranatharthi H.} and Snydman, {David R.} and {Bo Petersen}, Finn and Territo, {Mary C.} and Kathy Bartoni and Ken Miller and David Schenkein and Patrick Stiff and Reid Mattison and Mary Laughlin and Witold Rybka and {De Magalhaes-Silverman}, Margarida and Wingard, {John R.} and Toni Mazzuli and Clare Brennan and Sharon McDermott and Mauricio Vargas and Lee, {Ira C.}",
year = "2003",
month = "3",
day = "15",
doi = "10.1086/367836",
language = "English (US)",
volume = "36",
pages = "749--758",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

AU - Winston, Drew J.

AU - Yeager, Andrew M

AU - Chandrasekar, Pranatharthi H.

AU - Snydman, David R.

AU - Bo Petersen, Finn

AU - Territo, Mary C.

AU - Bartoni, Kathy

AU - Miller, Ken

AU - Schenkein, David

AU - Stiff, Patrick

AU - Mattison, Reid

AU - Laughlin, Mary

AU - Rybka, Witold

AU - De Magalhaes-Silverman, Margarida

AU - Wingard, John R.

AU - Mazzuli, Toni

AU - Brennan, Clare

AU - McDermott, Sharon

AU - Vargas, Mauricio

AU - Lee, Ira C.

PY - 2003/3/15

Y1 - 2003/3/15

N2 - In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.

AB - In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0037444029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037444029&partnerID=8YFLogxK

U2 - 10.1086/367836

DO - 10.1086/367836

M3 - Article

C2 - 12627359

AN - SCOPUS:0037444029

VL - 36

SP - 749

EP - 758

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -